Portfolio Rapha Capital Management

3DBio Therapeutics Receives Orphan Drug Designation for AuriNovo™ for Ear Reconstruction in Microtia Patients

By Kevin SlawinDecember 6, 2019February 4th, 2021No Comments

3D Bio Therapeutics, Inc.
3DBio Therapeutics Receives FDA Rare Pediatric Disease Designation for AuriNovo™ for Ear Reconstruction in Microtia Patients
December 6, 2019

Previous PostNexImmune Appoints Sol Barer as Chairman of the Board of Directors
Next Post3DBio Therapeutics Receives Orphan Drug Designation for AuriNovo™ for Ear Reconstruction in Microtia Patients

© 2024 Ponce Therapeutics. Privacy Policy | Terms & Conditions